Swiss Life Asset Management Ltd Raises Position in IDEXX Laboratories, Inc. $IDXX

Swiss Life Asset Management Ltd grew its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 37.3% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 36,450 shares of the company’s stock after buying an additional 9,910 shares during the period. Swiss Life Asset Management Ltd’s holdings in IDEXX Laboratories were worth $24,660,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of IDXX. Virtus Advisers LLC purchased a new position in IDEXX Laboratories in the third quarter worth about $26,000. Park Place Capital Corp purchased a new position in IDEXX Laboratories in the fourth quarter worth about $29,000. WealthCollab LLC purchased a new position in IDEXX Laboratories in the second quarter worth about $30,000. J.Safra Asset Management Corp purchased a new position in IDEXX Laboratories in the third quarter worth about $31,000. Finally, Greykasell Wealth Strategies Inc. purchased a new position in IDEXX Laboratories in the third quarter worth about $35,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have issued reports on IDXX shares. Stifel Nicolaus decreased their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Barclays decreased their target price on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Wall Street Zen cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Weiss Ratings reissued a “hold (c+)” rating on shares of IDEXX Laboratories in a report on Monday, April 27th. Finally, Citigroup assumed coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective on the stock. Seven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $751.00.

Insider Activity

In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 23,326 shares of the company’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $657.55, for a total value of $15,338,011.30. Following the completion of the transaction, the chief executive officer directly owned 83,606 shares in the company, valued at $54,975,125.30. This represents a 21.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Nimrata Hunt sold 2,693 shares of the company’s stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $661.54, for a total transaction of $1,781,527.22. Following the completion of the transaction, the executive vice president owned 19,899 shares of the company’s stock, valued at approximately $13,163,984.46. The trade was a 11.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 34,612 shares of company stock valued at $22,525,070. Company insiders own 0.79% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX opened at $532.00 on Tuesday. The firm has a 50 day moving average of $581.15 and a 200 day moving average of $648.62. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $41.96 billion, a price-to-earnings ratio of 39.18, a price-to-earnings-growth ratio of 3.26 and a beta of 1.58. IDEXX Laboratories, Inc. has a 12-month low of $496.61 and a 12-month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company’s revenue was up 14.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, research analysts anticipate that IDEXX Laboratories, Inc. will post 14.65 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.